Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have been available since around the year 2000 and used primarily in people with type 1 diabetes. In contrast to self-measured glucose, CGM can provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and hyperglycemia, and a detailed assessment of glycemic variability. Through a broad spectrum of derived glucose data, CGM should be a useful tool for clinical evaluation of new glucose-lowering medications and strategies. It is the only technology that can measure hyperglycemic and hypoglycemic exposure in ambulatory care, or provide data for comprehensive assessment of glucose variability. Other advantages of current CGM systems include the opportunity for improved self-management of glycemic control, with particular relevance to those at higher risk of or from hypoglycemia. We therefore summarize the current status and limitations of CGM from the perspective of clinical trials and derive suggested recommendations for how these should facilitate optimal CGM use and reporting of data in clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Self-citationDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Self-citationThe Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System
Bailey, T., Bode, B. W., Christiansen, M. P., Klaff, L. J., & Alva, S. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0378 · Cited by 685
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Deiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Self-citationThe effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
Bergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307 · cited 1×
“Despite suggestions for standardization of endpoints, no consistency has been reached, limiting comparability between CGM systems and publications using them.(51,52) Thus, some studies use historical parameters such as the MAGE, standard deviation (SD) or coefficient of variation about mean plasma glucose level, or th…”
Method
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Self-citationPrediction and prevention of hypoglycaemic events in type-1 diabetic patients using machine learning
Vehí, J., Contreras, I., Oviedo, S., Biagi, L., & Bertachi, A. (2020) · Health Informatics Journal · doi:10.1177/1460458219850682 · Cited by 76
“40 The participants of the clinical studies related to the datasets 1 41 and dataset 2 42 provided written informed consent on data utilisation.”
BackgroundFit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience
Godfrey, A., Vandendriessche, B., Bakker, J. P., Fitzer‐Attas, C., Gujar, N., Hobbs, M., Liu, Q., Northcott, C. A., Parks, V., Wood, W. A., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.12865 · Cited by 60
The History, Evolution and Future of Continuous Glucose Monitoring (CGM)
Bender, C., Vestergaard, P., & Cichosz, S. L. (2025) · Diabetology · doi:10.3390/diabetology6030017 · Cited by 43
Metadata
- Authors
- Schnell, O., Barnard, K., Bergenstal, R., Bosi, E., Garg, S., Guerci, B., Haak, T., Hirsch, I. B., Ji, L., Joshi, S. R., Kamp, M., Laffel, L., Mathieu, C., Polonsky, W. H., Snoek, F., & Home, P.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2017-07
- Volume
- 19
- Issue
- 7
- Pages
- 391-399
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2618019966
- Cited by
- 55
- References
- 15
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. https://app.cochat.ai/papers/10.1089/dia.2017.0054
- The paper
- Schnell, O., Barnard, K., Bergenstal, R., Bosi, E., Garg, S., Guerci, B., Haak, T., Hirsch, I. B., Ji, L., Joshi, S. R., Kamp, M., Laffel, L., Mathieu, C., Polonsky, W. H., Snoek, F., & Home, P. (2017). Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2017.0054
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.